Kleo, Green Cross collaborate on COVID-19 NK combination therapy

By The Science Advisory Board staff writers

March 31, 2020 -- Kleo Pharmaceuticals is joining forces with Green Cross LabCell (GCLC) of South Korea to advance testing of natural killer (NK) cell therapies as a potential treatment for COVID-19 patients.

Kleo had received approval from the U.S. Food and Drug Administration (FDA) earlier this year to proceed with an antibody recruiting molecule (ARM)-NK cell combination therapy clinical trial for treatment of newly diagnosed multiple myeloma patients. The ARM in that trial targets the CD38 cell surface protein and uses autologous cytokine-induced memory-like NK cells to kill tumor cells, according to the company.

Meanwhile, GCLC's allogeneic NK cells are in late-stage clinical development in immuno-oncology applications and are projected to advance into the clinic for COVID-19 in the second half of this year, according to Kleo.

Kleo's ARM technology platform can develop fully synthetic bifunctional molecules that redirect a patient's own antibodies for therapeutic effect. The ARM has multiple proposed mechanisms of action in the context of a COVID-19 therapeutic, according to the company.

For example, it acts as a neutralizing antibody to block direct binding on the virus to human cells and also utilizes immune effector cells to eliminate viral particles and infected cells. What's more, the ARM can produce a long-term vaccination effect by activating and expanding immune memory cells, Kleo said.

LabShares Newton offers free space for COVID-19 research
LabShares Newton is offering free, fully equipped biosafety level 2 lab space, facilities, and resources for researchers addressing the global COVID-19...
Vycellix, Avectas partner for product development
Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.
Frontera supercomputer aids COVID-19 drug development
Scientists are urgently working to build the first complete all-atom model of the SARS-CoV-2 coronavirus envelope, estimated to contain over 200 million...
New site shares real-time data about novel coronavirus genetics
DNAstack has introduced an online networking platform for sharing information about SARS-CoV-2, the virus that causes the respiratory disease COVID-19.
Comparative genomics confirms natural development of SARS-CoV-2
The available genetic data on SARS-CoV-2 indicate that it is not derived from any previously known virus, suggesting that it originated from either natural...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter